Selegiline, also known as l-deprenyl, is an antidepressant drug used to treat major depressive disorder, Parkinson’s disease, and Alzheimer’s disease. It is a monoamine oxidase inhibitor (MAOI) that has been used since the late 1980s to treat depression. While selegiline has been found to be effective in treating depression, there are some hidden side effects that doctors should be aware of. This article will explore the potential hidden side effects of selegiline and discuss ways to uncover the unknown.
Selegiline is an MAOI that works by blocking the enzyme monoamine oxidase from breaking down certain neurotransmitters, such as dopamine and norepinephrine. This allows these neurotransmitters to remain active in the brain longer, providing a mood boost. Selegiline is generally prescribed to treat major depressive disorder, Parkinson’s disease, and Alzheimer’s disease.
While selegiline has been found to be effective in treating depression, there are some hidden side effects that doctors should be aware of. The most common side effects of selegiline are nausea, vomiting, headache, insomnia, dry mouth, dizziness, and constipation. Other potential hidden side effects include anxiety, irritability, confusion, agitation, and hallucinations. Selegiline can also cause an increase in blood pressure and heart rate, which can be dangerous for those with pre-existing heart conditions.
Certain factors can increase the risk of experiencing hidden side effects from selegiline. These include age, gender, weight, and other medications being taken. Elderly patients are more likely to experience hidden side effects from selegiline, as they may have a lower tolerance for the drug. Women are also more likely to experience hidden side effects than men. Those who are overweight or obese may be more likely to experience hidden side effects due to the increased metabolism of the drug. Finally, those who are taking other medications may be more likely to experience hidden side effects due to potential drug interactions.
Due to the potential for hidden side effects, it is important for doctors to take steps to uncover the unknown. One way to do this is to discuss the potential side effects of selegiline with patients before they start taking the medication. It is also important to monitor patients closely while they are taking the medication, as this can help to identify any potential hidden side effects. Finally, doctors should be aware of any potential drug interactions and discuss them with patients before prescribing selegiline.
Selegiline is an effective treatment for major depressive disorder, Parkinson’s disease, and Alzheimer’s disease. However, there are some potential hidden side effects that doctors should be aware of. By discussing the potential side effects of selegiline with patients before they start taking the medication, monitoring patients closely while they are taking the medication, and being aware of any potential drug interactions, doctors can help to uncover the unknown and ensure that patients receive the best possible care.
1.
EBCC: European Breast Cancer Conference
2.
For patients with prostate cancer, long-term follow-up helps identify treatment side effects.
3.
Data-driven risk stratification guides childhood brain tumor treatment, reducing side effects
4.
Adult survivors of childhood cancer are at high risk for cognitive impairment, according to JAMA.
5.
Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit
1.
The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting
2.
Essential Techniques in Oncology and Quality Improvement
3.
Tumor Ecosystem Activity Biomarkers in Oncology
4.
Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained
5.
Advancements in Cancer Treatment and Survival Outcomes for Acute Myeloid Leukemia
1.
International Conference on Oncology, Cancer Prevention and Public Health
2.
International Conference on Cancer Nursing and Rehabilitation Strategies
3.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
4.
International Conference on Innovations in Critical Care for Oncology and Cardiology
5.
International Symposium on Oncology, Cardiology and Critical Care Innovations
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
How Nutrition Can Support Patients During Cancer Care
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation